BiVictriX Therapeutics Limited logo

BiVictriX Therapeutics Limited

BVX:JPJ / 10.50 GBX

Professional, scientific & technical services

BiVictriX Therapeutics Limited

About the Company

BiVictriX Therapeutics Ltd (“BVX”) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX’s first-in-class Bi-Cygni® bispecific Antibody Drug Conjugates (“ADCs”) combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.

Website

LinkedIn

Company Details

Incorporated15/02/2016
Admission Date11/09/2024
Securities in Issue94,133,948
Market Cap£9.8m

Contact Details

Email

info@bivictrix.com

AddressMereside Alderley Park, Alderley Edge, Manchester SK10 4TG

Documents & Downloads

Annual Reports and Accounts 2023 2960 KB 06 Nov 2025
Annual Reports and Accounts 2024 629 KB 06 Nov 2025

Other Contacts

Share Registrars Limited (Registrar)

Share Registrars Limited
The Courtyard
17 West Street
Farnham
Surrey GU9 7DR

Company Snapshot

StatusLive
Price10.50 GBX
Offer Interest10.00 GBX
TradingContinous
TickerBVX:JPJ
ClassOrd
SettlementCREST
IndustryProfessional, scientific & technical services
CountryUnited Kingdom
Company Number13470690
ISINGB00BNXH3K91
CurrencyGBX

Trade History

Date Quantity Mid Price Type Legend:
AT - Automatic Trade
AX - Agency Cross
PI - Primary Issuance
NT - Negotiated Trade
UT - Uncrossing Trade
04/02/2025 3,763 10.50
18/10/2024 48,282 10.50
30/09/2024 50,000 11.50
16/09/2024 100,000 11.00
16/09/2024 150,000 11.00
1

Leadership Team

Dr Michael Kauffman

Dr Michael Kauffman

Non-Executive Chairman

Tiffany Thorn

Tiffany Thorn

Chief Executive Officer

Petter Veiby

Petter Veiby

Non-Executive Director

Transacting on JP Jenkins

'Trading' on JP Jenkins is done via a matched bargain facility, this means that on instruction from your 'Broker' we will endeavour to match your shares against other buyer(s) or seller(s) who are also looking to transact. Requests to trade are performed on an availability basis, should an instruction be cancelled, altered or amended in anyway by an instruction from your broker then it shall lose its active place in the queue and reset to the end of list. JP Jenkins receives orders from brokers electronically via a FIX message or should your broker not have a FIX connection to our platform via telephone. If you do not have a UK registered stockbroker you will find a list of brokers that we have worked with to download here. You will also find a list of UK brokers at the bottom of this page and their contact details should you need to appoint one. JP Jenkins can ONLY take instruction to transact from a UK-registered stockbroker and cannot offer investment advice into companies displayed on our website. If you are unsure about trading please consult a financial advisor or wealth manager to assist you in determining what is right for you.

  • +44 845 528 1663

  • info@jpjenkins.com

  • JP Jenkins Ltd

    5th Floor

    101 Wigmore St

    London

    W1U 1QU

Copyright ©2025 JP Jenkins. All rights reserved. JP Jenkins is a company incorporated in England & Wales with registered number 08014724 and whose registered office is at 101 Wigmore Street, 5th Floor, London, England, W1U 1QU (JPJ). JPJ (FRN 1037394, PAN 25002) is authorised and regulated by the Financial Conduct Authority. This website is a financial promotion by JPJ. It is not intended to be a promotion of any individual investment opportunity and is not an offer to the public. JPJ acts for the companies listed on the website and provides services to authorised brokers but does not act for investors, consumers or any other person. The information on this website is obtained from the companies and other third parties and although JPJ considers these sources to be reliable, it makes no representation as to the accuracy of the information. JP Jenkins does not provide any advice on investing in unlisted shares generally or in the companies listed on the platform specifically, nor any legal, financial or tax advice of any kind. Nothing on this website and no communication from JPJ should be construed as an investment recommendation. If you have any doubt about the suitability of the investment, or you require financial advice, you should seek a personal recommendation from an appropriately qualified financial advisor. Investing in unlisted shares is high risk and should only be done as part of a diversified portfolio. Please read the RISK WARNINGS before making any investment decisions. Offers are only available through authorised persons. Any person resident outside the United Kingdom should ensure that they are not subject to any local regulations before investing. Nothing on this website constitutes an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. If you have any questions regarding these matters relating to information on this website you should consult a professional adviser.